CompletedPhase 1NCT05305105
Effects of Psilocybin in Post-Treatment Lyme Disease
Studying Lyme disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Johns Hopkins University
- Principal Investigator
- Albert Garcia-Romeu, PhDJohns Hopkins University
- Intervention
- Psilocybin(drug)
- Enrollment
- 20 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2025
Study locations (1)
- Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States
Collaborators
Steven & Alexandra Cohen Foundation · Usona Institute
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05305105 on ClinicalTrials.govOther trials for Lyme disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06785402Ceftriaxone for Post-Treatment Lyme DiseaseHackensack Meridian Health
- RECRUITINGPHASE3NCT07226882A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy AdultsPfizer
- RECRUITINGPHASE4NCT06451913Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))Biocodex
- RECRUITINGNANCT06915324Transcranial Direct Current Stimulation for Post Treatment Lyme DiseaseColumbia University
- RECRUITINGEARLY PHASE1NCT06611111Ceftriaxone Pulse Dose for Post-Treatment Lyme DiseaseState University of New York - Upstate Medical University
- ACTIVE NOT RECRUITINGNCT06835075Clinicaly Manifested Reinfections with Borrelia Burgdorferi Sensu LatoUniversity Medical Centre Ljubljana
- ACTIVE NOT RECRUITINGNCT06731179A Prospective Study to Evaluate the Role of T-Cell Dysfunction in Patients Who Present Symptoms Associated With Long COVID, Lyme Disease and Myalic Encephalomyelitis / Chronic Fatigue Syndrome Using the Vira Immune Fluorospot T Cell AssayViraxBio Labs
- RECRUITINGPHASE1, PHASE2NCT06511050Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue SyndromeIcahn School of Medicine at Mount Sinai